{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:31:11Z","timestamp":1790685071371,"version":"4.1.0"},"reference-count":71,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"MSD and Gilead Sciences"},{"name":"MSD, Astellas, Pfizer and honoraria by Gilead and Mylan, Inc."}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.2217\/fmb.15.34","type":"journal-article","created":{"date-parts":[[2015,5,22]],"date-time":"2015-05-22T14:21:28Z","timestamp":1432304488000},"page":"693-708","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":45,"title":["Isavuconazole: A new Extended Spectrum Triazole for Invasive Mold Diseases"],"prefix":"10.1080","volume":"10","author":[{"given":"Michelle R","family":"Ananda-Rajah","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Alfred Health, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Kontoyiannis","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control & Employee Health, Unit 1416, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,5,21]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01354-13"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01355-13"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02301-13"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-010-9324-3"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2015.990382"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2012.683859"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.286-293.2006"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.2217\/17460913.3.6.603"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S51340"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.279-285.2006"},{"key":"e_1_3_3_13_1","volume-title":"24th European Congress of Clinical Microbiologyand Infectious Diseases","author":"Maertens J","year":"2014","unstructured":"Maertens J , PattersonT , RahavGet al. A Phase 3, randomised, double-blind trial evaluating isavuconazole vs voriconazole for the primary treatment of invasive fungal disease caused by Aspergillus spp. or other filamentous fungi (SECURE) . Presented at : 24th European Congress of Clinical Microbiologyand Infectious Diseases . Barcelona, Spain , 10\u201313 May 2014 ."},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01111-13"},{"key":"e_1_3_3_15_1","volume-title":"54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM","author":"Najvar LK","year":"2014","unstructured":"Najvar LK , WiederholdNP , BocanegraR , OlivoM , KirkpatrickWR , PattersonTF . Isavuconazole is effective for the treatment of experimental cryptococcal meningitis . Presented at : 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM . Washington, DC, USA , 5\u20139 September 2014 ( Abstract no. M-427 )."},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2009.21.3.272"},{"key":"e_1_3_3_17_1","volume-title":"54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM","author":"Pfaller MA","year":"2014","unstructured":"Pfaller MA , MesserSA , DietrichRR , RhombergPR , JonesRN , CastanheiraM . Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: application of new clinical breakpoints and epidemiological cutoff values . Presented at : 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM . Washington, DC, USA , 5\u20139 September 2014 ( Abstract no. M-1091 )."},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl396"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01530-08"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/13693780802562969"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1309\/EXBVYAUPENBM285Y"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00863-13"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01512-07"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.06.003"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05910-11"},{"key":"e_1_3_3_26_1","volume-title":"54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM","author":"Chandra J","year":"2014","unstructured":"Chandra J , MukherjeeP , GhannoumMA . Resistance mechanisms to azoles in moulds . Presented at : 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM . Washington, DC, USA , 5\u20139 September 2014 ( Abstract no. M-1278 )."},{"key":"e_1_3_3_27_1","volume-title":"54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM","author":"Jim\u00e9nez-Ortigosa C","year":"2014","unstructured":"Jim\u00e9nez-Ortigosa C , MatsumotoS , FouantMM , KovandaL , PerlinDS . Assessing isavuconazole-induced resistance in Aspergillus fumigatus . Presented at : 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM . Washington, DC, USA , 5\u20139 September 2014 ( Abstract no. M-1081 )."},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03890.x"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12148"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01141-13"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.3109\/13693786.2010.508469"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01601-08"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010080"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00931-09"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01279-12"},{"key":"e_1_3_3_36_1","volume-title":"54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM","author":"Desai A","year":"2014","unstructured":"Desai A , KovandaL , KowalskiD , LuQ , TownsendR . Isavuconazole (ISA) population pharmacokinetic modeling from Phase 1 and Phase 3 clinical trials and target attainment analysis . Presented at : 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM . Washington, DC, USA , 5\u20139 September 2014 ( Abstract no. A-697 )."},{"key":"e_1_3_3_37_1","volume-title":"54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM","author":"Andes D","year":"2014","unstructured":"Andes D , GhannoumM , KovandaLet al. Outcomes by minimum inhibitory concentrations from isavuconazole Phase 3 trial of invasive aspergillosis (SECURE) . 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM . Washington, DC, USA , 5\u20139 September 2014 ( Abstract No. M17\u201361 )."},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03261-14"},{"key":"e_1_3_3_39_1","volume-title":"22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).","author":"Schmitt-Hoffmann AH","year":"2012","unstructured":"Schmitt-Hoffmann AH , RichterWF . Isavuconazole is widely distributed in rat tissue . Presented at : 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).London, UK , 31 March\u20133 April 2012 ( Abstract no. P-863 )."},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn431"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01276-09"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00319-09"},{"key":"e_1_3_3_43_1","unstructured":"Astellas : FDA advisory committee briefing document: isavuconazonium-invasive aspergillosis and invasive mucormycosis . www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM430748.pdf ."},{"key":"e_1_3_3_44_1","volume-title":"53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM","author":"Yamazaki T","year":"2013","unstructured":"Yamazaki T , DesaiA , PearlmanH , KowalskiD , LademacherC , TownsendR . No effect on pharmacokinetic and pharmacodynamic parameters of warfarin after co-administration with isavuconazole . Presented at : 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM . CL, USA , 10\u201313 September 2013 ( Abstract no. A-448 )."},{"key":"e_1_3_3_45_1","volume-title":"114th American Society for Clinical Pharmacology and Therapeutics (ASCPT) ASM","author":"Yamazaki T","year":"2013","unstructured":"Yamazaki T , PearlmanH , DesaiA , KowalskiD , TownsendR . Effect of multiple doses of isavuconazole on the pharmacokinetics of CYP3A4 substrate cyclosporine in healthy subjects . Presented at : 114th American Society for Clinical Pharmacology and Therapeutics (ASCPT) ASM . IN, USA , 5\u20139 March 2013 ( Abstract no. PIII-76 )."},{"key":"e_1_3_3_46_1","volume-title":"American Society for Clinical Pharmacology and Therapeutics (ASCPT) ASM","author":"Yamazaki T","year":"2014","unstructured":"Yamazaki T , DesaiA , KowalskiDLet al. Effect of multiple doses of isavuconazole on the pharmacokinetics of methotrexate in healthy subjects . Presented at : American Society for Clinical Pharmacology and Therapeutics (ASCPT) ASM . GA, USA , 18\u201322 Match 2014 ."},{"key":"e_1_3_3_47_1","volume-title":"114th American Society for Clinical Pharmacology and Therapeutics (ASCPT) ASM","author":"Yamazaki T","year":"2013","unstructured":"Yamazaki T , PearlmanH , DesaiA , KowalskiD , TownsendR . Effect of multiple doses of isavuconazole on the pharmacokinetics of sirolimus in healthy subjects . 114th American Society for Clinical Pharmacology and Therapeutics (ASCPT) ASM . IN, USA , 5\u20139 March 2013 ( Abstract no. PIII-75 )."},{"key":"e_1_3_3_48_1","volume-title":"114th American Society for Clinical Pharmacology and Therapeutics (ASCPT) ASM","author":"Desai A","year":"2013","unstructured":"Desai A , PearlmanH , YamazakiT , KowalskiD , TownsendR . Effect of multiple doses of isavuconazole on the pharmacokinetics of CYP3A4 substrate tacrolimus in healthy subjects . Presented at : 114th American Society for Clinical Pharmacology and Therapeutics (ASCPT) ASM . IN, USA , 5\u20139 March 2013 ( Abstract no. P-71 )."},{"key":"e_1_3_3_49_1","volume-title":"114th American Society for Clinical Pharmacology and Therapeutics (ASCPT) ASM","author":"Desai A","year":"2013","unstructured":"Desai A , HowiesonC , YamazakiT , KowalskiD , TownsendR . Isavuconazole does not affect prednisolone pharmacokinetics in healthy subjects following co-administration of multiple doses of isavuconazole . Presented at : 114th American Society for Clinical Pharmacology and Therapeutics (ASCPT) ASM . IN, USA , 5\u20139 March 2013 ( Abstract no. PI-70 )."},{"key":"e_1_3_3_50_1","unstructured":"ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ ."},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1086\/588660"},{"key":"e_1_3_3_52_1","volume-title":"ID Week","author":"Kontoyiannis D","year":"2014","unstructured":"Kontoyiannis D , GiladiM , LeeMet al. A Phase 3, randomized, double-blind, non-inferiority trial to evaluate efficacy and safety of isavuconazole versus voriconazole in patients with invasive mold disease (SECURE): outcomes in invasive aspergillosis patients . Presented at : ID Week . PA, USA , 8\u201312 October 2014 ."},{"key":"e_1_3_3_53_1","volume-title":"54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM","author":"Marr KA","year":"2014","unstructured":"Marr KA , BowE , HeinzWet al. A Phase 3 randomized, double-blind, non-inferiority trial evaluating isavuconazole (ISA) vs voriconazole (VRC) for the primary treatment of invasive mold infection (SECURE): outcomes in subset of patients with hematologic malignancies (HM) . Presented at : 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM . Washington, DC, USA , 5\u20139 September 2014 ( Abstract no. M-1757 )."},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.740561"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03548.x"},{"key":"e_1_3_3_56_1","volume-title":"ID Week ASM","author":"Raad I","year":"2014","unstructured":"Raad I , MullaneKM , SelleslagDet al. A Phase 3, randomized, double-blind, non-inferiority trial to evaluate efficacy and safety of isavuconazole vs. voriconazole in patients with invasive mold disease (IMD): outcomes in patients with pulmonary infections . Presented at : ID Week ASM . PA, USA , 8\u201312 October 2014 ( Abtract no. 825 )."},{"key":"e_1_3_3_57_1","volume-title":"54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM","author":"Ullmann AJ","year":"2014","unstructured":"Ullmann AJ , ShohamS , HuangW , MujaisS . A Phase 3 randomized, double-blind, non-inferiority trial evaluating isavuconazole (ISA) vs voriconazole (VRC) for the primary treatment of invasive fungal disease (IFD) caused by Aspergillus spp. or other filamentous fungi (SECURE): outcomes by malignancy status . Presented at : 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM . Washington, DC, USA , 5\u20139 September 2014 ( Abstract no. M-1756 )."},{"key":"e_1_3_3_58_1","volume-title":"ID Week ASM","author":"Marty FM","year":"2014","unstructured":"Marty FM , PerfectJR , CornelyOAet al. An open-label Phase 3 study of isavuconazole (VITAL): focus on mucormycosis . Presented at : ID Week ASM . PA, USA , 8\u201312 October 2014 ( Abstract no. 824 )."},{"key":"e_1_3_3_59_1","volume-title":"54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM","author":"Thompson G","year":"2014","unstructured":"Thompson G , RendonA , SantosRet al. Outcomes in patients with invasive fungal disease caused by dimorphic fungi treated with isavuconazole: experience from the VITAL trial . Presented at : 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM . Washington, DC, USA , 5\u20139 September 2014 ( Abstract no. M-1775 )."},{"key":"e_1_3_3_60_1","volume-title":"54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM","author":"Cornely OA","year":"2014","unstructured":"Cornely OA , Ostrosky-ZeichnerL , RahavGet al. Outcomes in patients with invasive mold disease caused by fusarium or scedosporium spp. treated with isavuconazole: experience from the VITAL and SECURE trials . Presented at : 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM . Washington, DC, USA , 5\u20139 September 2014 ( Abstract no. M-1760 )."},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-316430"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir866"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2010.03456.x"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70238-3"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.03176-13"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-013-0552-6"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku311"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1086\/651263"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1086\/651262"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku227"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-172007"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70265-8"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e32834e0680"}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fmb.15.34","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:38:39Z","timestamp":1719124719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fmb.15.34"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.2217\/fmb.15.34"],"URL":"https:\/\/doi.org\/10.2217\/fmb.15.34","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-05-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}